Nagahama S, Chen Y F, Lindheimer M D, Oparil S
J Pharmacol Exp Ther. 1986 Nov;239(2):426-32.
Administration of LY171555 (1 mg/kg i.v.) decreased mean arterial pressure (MAP) and heart rate in both pentobarbital- and urethane-anesthesized Sprague-Dawley rats. The depressor response to LY171555 in pentobarbital-anesthetized rats was sustained for at least 30 min, but in urethane-anesthetized rats lasted only approximately 3 min after LY171555 injection. In pentobarbital-anesthetized rats, pretreatment with domperidone (0.5 mg/kg) or metoclopramide (5 mg/kg) attenuated the depressor action of LY171555, whereas pretreatment with d(CH2)5Tyr(Me)arginine vasopressin (AVP) (10 micrograms/kg) only delayed the recovery phase of the depressor response to LY171555. In contrast, LY171555 administered to urethane-anesthetized rats after domperidone pretreatment induced a pressor response which was blocked completely by d(CH2)5Tyr(Me)AVP. Metoclopramide pretreatment in urethane-anesthetized rats prevented the decreases in MAP and heart rate induced by LY171555, whereas pretreatment with d(CH2)5Tyr(Me)AVP delayed the recovery phase of the depressor response. Pretreatment with d(CH2)5Tyr(Me)AVP per se decreased basal MAP in the urethane-anesthetized group, but not in pentobarbital-anesthetized rats. Basal plasma norepinephrine, epinephrine and AVP levels were higher in urethane-anesthetized rats than in the pentobarbital-anesthetized group. LY171555 administration decreased plasma norepinephrine without altering plasma epinephrine in both groups and induced a significant increase in plasma AVP which was greater in the urethane-anesthetized rats than in pentobarbital-anesthetized animals. These results suggest that LY171555 decreases MAP and heart rate in anesthetized rats by inhibiting norepinephrine release from nerve endings through the peripheral dopamine D2 receptor and that the time course of the depressor response may be altered by LY171555-induced AVP release, the magnitude of which appears to be dependent on the anesthetic agent.
静脉注射LY171555(1毫克/千克)可降低戊巴比妥和乌拉坦麻醉的Sprague-Dawley大鼠的平均动脉压(MAP)和心率。在戊巴比妥麻醉的大鼠中,对LY171555的降压反应持续至少30分钟,但在乌拉坦麻醉的大鼠中,LY171555注射后仅持续约3分钟。在戊巴比妥麻醉的大鼠中,用多潘立酮(0.5毫克/千克)或甲氧氯普胺(5毫克/千克)预处理可减弱LY171555的降压作用,而用d(CH2)5Tyr(Me)精氨酸血管加压素(AVP)(10微克/千克)预处理仅延迟了对LY171555降压反应的恢复阶段。相比之下,在多潘立酮预处理后给乌拉坦麻醉的大鼠注射LY171555会诱导升压反应,该反应被d(CH2)5Tyr(Me)AVP完全阻断。在乌拉坦麻醉的大鼠中,甲氧氯普胺预处理可防止LY171555引起的MAP和心率下降,而用d(CH2)5Tyr(Me)AVP预处理则延迟了降压反应的恢复阶段。用d(CH2)5Tyr(Me)AVP本身预处理可降低乌拉坦麻醉组的基础MAP,但对戊巴比妥麻醉的大鼠无此作用。乌拉坦麻醉的大鼠的基础血浆去甲肾上腺素、肾上腺素和AVP水平高于戊巴比妥麻醉组。在两组中,注射LY171555均可降低血浆去甲肾上腺素水平,而不改变血浆肾上腺素水平,并诱导血浆AVP显著升高,乌拉坦麻醉的大鼠升高幅度大于戊巴比妥麻醉的动物。这些结果表明,LY171555通过外周多巴胺D2受体抑制神经末梢去甲肾上腺素释放来降低麻醉大鼠的MAP和心率,并且LY171555诱导的AVP释放可能会改变降压反应的时间进程,其幅度似乎取决于麻醉剂。